Eosinophilic Esophagitis Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Eosinophilic Esophagitis Pipeline Insights 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Eosinophilic Esophagitis Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Eosinophilic Esophagitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

* In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
* In August 2025, Eupraxia Pharmaceuticals Inc. conducted a Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity.
* In August 2025, Uniquity One (UNI) organized a Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
* DelveInsight's Eosinophilic Esophagitis pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Eosinophilic Esophagitis treatment.
* The leading Eosinophilic Esophagitis Companies such as Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.
* Promising Eosinophilic Esophagitis Therapies such as Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide , and others.

Discover how the Eosinophilic Esophagitis treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Eosinophilic Esophagitis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eosinophilic Esophagitis Emerging Drugs Profile

* APT-1011: Ellodi Pharmaceuticals

APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in clinical development, following successful completion of FLUTE I and FLUTE II. It has been granted orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis.

* IRL201104: Revolo Biotherapeutics

IRL201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a number of preclinical models. It has successfully completed Phase I clinical development and has the potential to be the first Immune Resetting Asthma Drug (IMRAD). 1104 is a novel linear peptide, derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It may provide remission for many allergic diseases. 1104 engages a novel target on macrophages and is a first-in-class modulator of the macrophage response. This response engages not only the effector arm of the immune system, but the regulatory arm as well. Currently the product is in Phase II stage of development for the treatment of patients with eosinophilic esophagitis (EoE) and other Th2 allergic diseases.

* AQ280: Aqilion

AQ280 is an oral, small-molecule, super selective JAK1 inhibitor. JAK1 is an enzyme, a kinase that accelerates inflammatory processes, which, among other things effects allergy and fibrosis. By inhibiting its mechanism, it is possible to reduce symptoms and disease development in chronic inflammatory diseases. Within the Regulus program, Aqilion is developing AQ280, which is a super selective JAK1 inhibitor, as a treatment of the chronic disease eosinophilic esophagitis. Data describing the pharmacokinetic profile, safety and tolerability of the drug candidate was evaluated between every dose escalation. Now, data has been collected for all dose groups and the database has been locked for statistical analysis. Currently the product is in Phase I stage of development for the treatment of patients with eosinophilic esophagitis (EoE).

The Eosinophilic Esophagitis pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
* Eosinophilic Esophagitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.

Get a detailed analysis of the latest innovations in the Eosinophilic Esophagitis pipeline. Explore DelveInsight's expert-driven report today! @ Eosinophilic Esophagitis Unmet Needs [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eosinophilic Esophagitis Companies

Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous

Eosinophilic Esophagitis Products have been categorized under various Molecule types such as

* Peptide
* Protein
* Propylene glycols
* Cell Therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Eosinophilic Esophagitis Therapies and key drug developments @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Eosinophilic Esophagitis Pipeline Report

* Coverage- Global
* Eosinophilic Esophagitis Companies- Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma , and others.
* Eosinophilic Esophagitis Therapies- Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide , and others.
* Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Eosinophilic Esophagitis drug development? Find out in DelveInsight's exclusive Eosinophilic Esophagitis Pipeline Report-access it now! @ Eosinophilic Esophagitis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Eosinophilic Esophagitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Eosinophilic Esophagitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* APT-1011: Ellodi Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IRL201104: Revolo Biotherapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AQ280: Aqilion
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Eosinophilic Esophagitis Key Companies
* Eosinophilic Esophagitis Key Products
* Eosinophilic Esophagitis- Unmet Needs
* Eosinophilic Esophagitis- Market Drivers and Barriers
* Eosinophilic Esophagitis- Future Perspectives and Conclusion
* Eosinophilic Esophagitis Analyst Views
* Eosinophilic Esophagitis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-pipeline-outlook-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.